A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

Leukemia

Volumn 23, Issue 9, 2009, Pages 1554-1576

  Ikezoe, T ^a   Yang, J ^a   Nishioka, C ^a   Takezaki, Y ^a   Tasaka, T ^b   Togitani, K ^a   Koeffler, H P ^c   Yokoyama, A ^a  

^a KOCHI UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Polo like kinase 1

Indexed keywords

5 (5,6 DIMETHOXY 1H BENZIMIDAZOL 1 YL) 3 ((2 (TRIFLUOROMETHYL)BENZYL)OXY)THIOPHENE 2 CARBOXAMIDE; 5-(5,6-DIMETHOXY-1H-BENZIMIDAZOL-1-YL)-3-((2-(TRIFLUOROMETHYL)BENZYL)OXY)THIOPHENE-2-CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; CELL CYCLE PROTEIN; MESSENGER RNA; ONCOPROTEIN; POLO LIKE KINASE 1; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; THIOPHENE DERIVATIVE; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; LEUKEMIA; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; BENZIMIDAZOLES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE; HUMANS; LEUKEMIA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; THIOPHENES; VINCRISTINE;

EID: 84862981566     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.94     Document Type: Article

References (30)

1. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
2. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24: 267-276.
3. Lake RJ, Jelinek WR. Cell cycle-and terminal differentiationassociated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 1993; 13: 7793-7801.
4. Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995; 129: 1617-1628.
5. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135: 1701-1713.
6. Ohkura H, Hagan IM, Glover DM. The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells. Genes Dev 1995; 9: 1059-1073.
7. Mundt KE, Golsteyn RM, Lane HA, Nigg EA. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 1997; 239: 377-385.
8. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 2000; 12: 405-411.
9. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148-152.
10. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005; 11: 5644-5650.
11. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446: 442-450.
12. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 543-549.
13. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405.
14. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF et al. In vitro biological activity of a novel smallmolecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007; 6: 450-459.
15. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5: 2522-2530.
16. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007; 6: 1851-1857.
17. Ikezoe T, Bandobashi K, Yang Y, Takeuchi S, Sekiguchi N, Sakai S et al. HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. Leuk Res 2006; 30: 1005-1011.
18. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Taguchi H. Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway. Leukemia 2007; 21: 1044-1049.
19. Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004; 104: 237-242.
20. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007; 31: 673-682.
21. Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008; 32: 1382-1392.
22. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005; 4: 578-586.
23. Tamura Y, Simizu S, Muroi M, Takagi S, Kawatani M, Watanabe N et al. Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis. Oncogene 2009; 28: 107-116.
24. Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B. Evaluation of polo-like kinase 1 inhibition on the G2/M checkpoint in acute myelocytic leukemia. Eur J Pharmacol 2008; 591: 102-105.
25. Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R et al. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem 1996; 271: 19402-19408.
26. Dai W, Li Y, Ouyang B, Pan H, Reissmann P, Li J et al. PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes Chromosomes Cancer 2000; 27: 332-336.
27. Kottaridis PD, Gale RE, Frew ME, Frew ME, Bowen DT, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
28. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279: 25549-25561.
29. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110: 2034-2040.
30. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-5809.